{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:26:13Z","timestamp":1792517173410,"version":"4.5.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.pharma.2025.01.012","type":"journal-article","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T07:55:28Z","timestamp":1738223728000},"page":"605-616","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of antioxidant excipients on N-nitrosamine formation and bioequivalence in metformin formulations (review article)"],"prefix":"10.1016","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1358-1479","authenticated-orcid":false,"given":"G\u00fcler Ya\u011fmur","family":"Aky\u00fcz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharma.2025.01.012_bib0350","unstructured":"WHO. Information note: nitrosamine impurities: World Health Organization 2019 [updated Internet; cited 2024 Nov 22]. Available from: https:\/\/www.who.int\/news\/item\/20-11-2019-information-note-nitrosamine-impurities."},{"key":"#cr-split#-10.1016\/j.pharma.2025.01.012_bib0355.1","unstructured":"EMA. Referral under Article 31 of Directive 2001\/83\/EC angiotensin-II-receptor antagonists (sartans) containing a tetrazole group [Internet]. European Medicines Agency"},{"key":"#cr-split#-10.1016\/j.pharma.2025.01.012_bib0355.2","unstructured":"2019 [cited 2025 Jan 16]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-chmp-assessment-report_en.pdf."},{"key":"10.1016\/j.pharma.2025.01.012_bib0360","unstructured":"FDA. M7(R1) Assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk: Guidance for industry. [Internet]. U.S. Food and Drug Administration; 2018 [cited 2024 Nov 7]. Available from: https:\/\/www.fda.gov\/media\/85885\/download."},{"issue":"18","key":"10.1016\/j.pharma.2025.01.012_bib0365","doi-asserted-by":"crossref","first-page":"9465","DOI":"10.3390\/ijerph18189465","article-title":"Estimated cancer risks associated with nitrosamine contamination in commonly used medications","volume":"18","author":"Li","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.pharma.2025.01.012_bib0370","series-title":"Lessons learnt from presence of N-nitrosamine impurities in sartan medicines [Internet]","year":"2020"},{"issue":"7","key":"10.1016\/j.pharma.2025.01.012_bib0375","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1007\/s12325-018-0694-0","article-title":"Combination glucose-lowering therapy plans in T2DM: case-based considerations","volume":"35","author":"Blonde","year":"2018","journal-title":"Adv Ther"},{"issue":"5","key":"10.1016\/j.pharma.2025.01.012_bib0380","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1159\/000381643","article-title":"Metformin: an old drug for the treatment of diabetes but a new drug for the protection of the endothelium","volume":"24","author":"Kinaan","year":"2015","journal-title":"Med Princ Pract"},{"key":"10.1016\/j.pharma.2025.01.012_bib0385","series-title":"Number of metformin prescriptions in the U.S. from 2004 to 2024 (in millions) [Internet]","author":"Mikulic","year":"2024"},{"issue":"4","key":"10.1016\/j.pharma.2025.01.012_bib0390","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.clinthera.2017.02.008","article-title":"Type 2 diabetes mellitus treatment patterns across Europe: a population-based multi-database study","volume":"39","author":"Overbeek","year":"2017","journal-title":"Clin Ther"},{"key":"10.1016\/j.pharma.2025.01.012_bib0395","first-page":"856","article-title":"Description of a French population of diabetics treated followed up by general practitioners","volume":"302","author":"Fruchart","year":"2023","journal-title":"Stud Health Technol Inform"},{"key":"10.1016\/j.pharma.2025.01.012_bib0400","series-title":"HSA recalls three out of 46 metformin medicines due to NDMA impurities [Internet]","year":"2019"},{"key":"10.1016\/j.pharma.2025.01.012_bib0405","series-title":"FDA updates and press announcements on NDMA in metformin [Internet]","year":"2021"},{"key":"10.1016\/j.pharma.2025.01.012_bib0410","series-title":"Viona Pharmaceuticals Inc. issues voluntary nationwide recall of Metformin HCl Extended-Release Tablets, USP 750mg, due to the detection of N-nitrosodimethylamine (NDMA) impurity [Internet]","year":"2022"},{"key":"10.1016\/j.pharma.2025.01.012_bib0415","series-title":"The Board of Pharmacy has received notice of the following product recall [Internet]","year":"2022"},{"issue":"1","key":"10.1016\/j.pharma.2025.01.012_bib0420","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1208\/s12248-021-00670-1","article-title":"Evaluation of excipient risk in BCS Class I and III Biowaivers","volume":"24","author":"Metry","year":"2022","journal-title":"AAPS J"},{"issue":"10","key":"10.1016\/j.pharma.2025.01.012_bib0425","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1007\/s11095-012-0767-8","article-title":"Impact of excipient interactions on drug bioavailability from solid dosage forms","volume":"29","author":"Panakanti","year":"2012","journal-title":"Pharm Res"},{"issue":"5","key":"10.1016\/j.pharma.2025.01.012_bib0430","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1208\/s12248-014-9620-9","article-title":"A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability, Pharm Res 12, 413-420, 1995--backstory of BCS","volume":"16","author":"Shah","year":"2014","journal-title":"AAPS J"},{"key":"10.1016\/j.pharma.2025.01.012_bib0435","unstructured":"ICH. M9 guideline: Biopharmaceutics classification system-based biowaivers [Internet]. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use 2019 [cited 2024 Nov 7]. Available from: https:\/\/database.ich.org\/sites\/default\/files\/M9_Guideline_Step4_2019_1116.pdf."},{"key":"10.1016\/j.pharma.2025.01.012_bib0440","unstructured":"ICH. M13A guideline: Bioequivalence for immediate-release solid oral dosage forms [Internet]. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use 2022 [cited 2024 Nov 27]. Available from: https:\/\/database.ich.org\/sites\/default\/files\/M13A_Guideline_Step4_2022.pdf."},{"key":"10.1016\/j.pharma.2025.01.012_bib0445","series-title":"Metformin: Product-specific bioequivalence guidance [Internet]","year":"2024"},{"key":"10.1016\/j.pharma.2025.01.012_bib0450","series-title":"M9 Biopharmaceutics Classification System Based Biowaivers [Internet]","year":"2021"},{"issue":"9","key":"10.1016\/j.pharma.2025.01.012_bib0455","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15092366","article-title":"Effect of the similarity of formulations and excipients of approved generic drug products on in vivo bioequivalence for putative biopharmaceutics classification system class III drugs","volume":"15","author":"Ren","year":"2023","journal-title":"Pharmaceutics"},{"issue":"4","key":"10.1016\/j.pharma.2025.01.012_bib0460","doi-asserted-by":"crossref","first-page":"539","DOI":"10.3390\/ph16040539","article-title":"Effect of excipients on the quality of drug formulation and immediate release of generic metformin HCl tablets","volume":"16","author":"Arafat","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"issue":"3","key":"10.1016\/j.pharma.2025.01.012_bib0465","doi-asserted-by":"crossref","first-page":"60.","DOI":"10.1208\/s12248-022-00711-3","article-title":"A critical overview of the biological effects of excipients (Part I): impact on gastrointestinal absorption","volume":"24","author":"Martinez","year":"2022","journal-title":"AAPS J"},{"key":"10.1016\/j.pharma.2025.01.012_bib0470","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ejps.2014.09.004","article-title":"Interactions between active pharmaceutical ingredients and excipients affecting bioavailability: impact on bioequivalence","volume":"65","author":"Garcia-Arieta","year":"2014","journal-title":"Eur J Pharm Sci"},{"issue":"1","key":"10.1016\/j.pharma.2025.01.012_bib0475","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/jps.20477","article-title":"Biowaiver monographs for immediate release solid oral dosage forms: acetaminophen (paracetamol)","volume":"95","author":"Kalantzi","year":"2006","journal-title":"J Pharm Sci"},{"issue":"4","key":"10.1016\/j.pharma.2025.01.012_bib0480","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1208\/s12248-016-9928-8","article-title":"The effects of pharmaceutical excipients on gastrointestinal tract metabolic enzymes and transporters-an update","volume":"18","author":"Zhang","year":"2016","journal-title":"AAPS J"},{"issue":"21","key":"10.1016\/j.pharma.2025.01.012_bib0485","doi-asserted-by":"crossref","first-page":"8224","DOI":"10.3390\/ijms21218224","article-title":"Pharmaceutical excipients and drug metabolism: a mini-review","volume":"21","author":"Patel","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.pharma.2025.01.012_bib0490","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/j.xphs.2021.01.011","article-title":"Biowaiver monographs for immediate release solid oral dosage forms: metformin hydrochloride","volume":"110","author":"Metry","year":"2021","journal-title":"J Pharm Sci"},{"issue":"3","key":"10.1016\/j.pharma.2025.01.012_bib0495","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1208\/s12248-022-00702-4","article-title":"International Regulatory Collaboration on the analysis of nitrosamines in metformin-containing medicines","volume":"24","author":"Keire","year":"2022","journal-title":"AAPS J"},{"key":"10.1016\/j.pharma.2025.01.012_bib0500","series-title":"Questions and answers on \u201cInformation on nitrosamines for marketing authorization holders\u201d [Internet]","year":"2024"},{"key":"10.1016\/j.pharma.2025.01.012_bib0505","series-title":"Control of nitrosamine impurities in human drugs. U.S. Food and Drug Administration [Internet]","year":"2024"},{"key":"10.1016\/j.pharma.2025.01.012_bib0510","doi-asserted-by":"crossref","first-page":"115066","DOI":"10.1016\/j.jpba.2022.115066","article-title":"N-Nitrosodimethylamine formation in metformin hydrochloride sustained-release tablets: effects of metformin and hypromellose used in drug product formulation","volume":"222","author":"Hao","year":"2023","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.pharma.2025.01.012_bib0515","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.3390\/pharmaceutics15082015","article-title":"Modeling the impact of excipients selection on nitrosamine formation towards risk mitigation","volume":"15","author":"Berardi","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.pharma.2025.01.012_bib0520","series-title":"European Pharmacopoeia (10th ed.): Monograph on metformin hydrochloride [Internet]","year":"2019"},{"issue":"6","key":"10.1016\/j.pharma.2025.01.012_bib0525","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.xphs.2022.04.016","article-title":"A nitrite excipient database: a useful tool to support n-nitrosamine risk assessments for drug products","volume":"112","author":"Boetzel","year":"2023","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.pharma.2025.01.012_bib0530","doi-asserted-by":"crossref","first-page":"124832","DOI":"10.1016\/j.ijpharm.2024.124832","article-title":"Nitrosamine mitigation: NDMA impurity formation and its inhibition in metformin hydrochloride tablets","volume":"666","author":"Shakleya","year":"2024","journal-title":"Int J Pharm"},{"issue":"7","key":"10.1016\/j.pharma.2025.01.012_bib0535","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s11095-021-03068-y","article-title":"Gel strength of hydrophilic matrix tablets in terms of in vitro robustness","volume":"38","author":"Goldoozian","year":"2021","journal-title":"Pharm Res"},{"key":"10.1016\/j.pharma.2025.01.012_bib0540","doi-asserted-by":"crossref","first-page":"121740","DOI":"10.1016\/j.ijpharm.2022.121740","article-title":"Avoiding N-nitrosodimethylamine formation in metformin pharmaceuticals by limiting dimethylamine and nitrite","volume":"620","author":"Schlingemann","year":"2022","journal-title":"Int J Pharm"},{"key":"10.1016\/j.pharma.2025.01.012_bib0545","series-title":"Quantitation of reactive nitrosating agents in pharmaceutical excipients for N-Nitrosamine risk assessments","author":"Yamamoto","year":"2023"},{"key":"10.1016\/j.pharma.2025.01.012_bib0550","series-title":"Note for guidance on inclusion of antioxidants and antimicrobial preservatives in medicinal products. European Medicines Agency [Internet]","year":"2018"},{"issue":"8","key":"10.1016\/j.pharma.2025.01.012_bib0555","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1016\/j.xphs.2024.03.005","article-title":"Lack of effect of antioxidants on Biopharmaceutics Classification System (BCS) Class III drug permeability","volume":"113","author":"Chiang Yu","year":"2024","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.pharma.2025.01.012_bib0560","series-title":"Inactive Ingredients Database Download [Internet]","year":"2024"},{"issue":"9","key":"10.1016\/j.pharma.2025.01.012_bib0565","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1016\/j.xphs.2024.05.033","article-title":"Antioxidants had no effects on the in-vitro permeability of BCS III model drug substances","volume":"113","author":"Lu","year":"2024","journal-title":"J Pharm Sci"},{"issue":"16","key":"10.1016\/j.pharma.2025.01.012_bib0570","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.4155\/fmc.11.149","article-title":"Drug-permeability and transporter assays in Caco-2 and MDCK cell lines","volume":"3","author":"Volpe","year":"2011","journal-title":"Future Med Chem"},{"issue":"5","key":"10.1016\/j.pharma.2025.01.012_bib0575","doi-asserted-by":"crossref","first-page":"647","DOI":"10.3390\/pharmaceutics16050647","article-title":"Effect of antioxidants in medicinal products on intestinal drug transporters","volume":"16","author":"Kulkarni","year":"2024","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.pharma.2025.01.012_bib0580","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1124\/pr.118.015578","article-title":"Organic cation transporters in health and disease","volume":"72","author":"Koepsell","year":"2020","journal-title":"Pharmacol Rev"},{"issue":"2","key":"10.1016\/j.pharma.2025.01.012_bib0585","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2165\/11534750-000000000-00000","article-title":"Clinical pharmacokinetics of metformin","volume":"50","author":"Graham","year":"2011","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"10.1016\/j.pharma.2025.01.012_bib0590","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1016\/j.xphs.2017.04.078","article-title":"Transporters involved in metformin pharmacokinetics and treatment response","volume":"106","author":"Liang","year":"2017","journal-title":"J Pharm Sci"},{"issue":"9","key":"10.1016\/j.pharma.2025.01.012_bib0595","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1097\/FPC.0b013e3283561666","article-title":"Association of genetic variation in the organic cation transporters OCT1, OCT2 and multidrug and toxin extrusion 1 transporter protein genes with the gastrointestinal side effects and lower BMI in metformin-treated type 2 diabetes patients","volume":"22","author":"Tarasova","year":"2012","journal-title":"Pharmacogenet Genomics"},{"issue":"5","key":"10.1016\/j.pharma.2025.01.012_bib0600","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1002\/cpt.701","article-title":"Genetic polymorphisms in organic cation transporter 1 attenuates hepatic metformin exposure in humans","volume":"102","author":"Sundelin","year":"2017","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.pharma.2025.01.012_bib0605","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1172\/JCI30558","article-title":"Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action","volume":"117","author":"Shu","year":"2007","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.pharma.2025.01.012_bib0610","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1021\/acs.molpharmaceut.0c01104","article-title":"Effect of pharmaceutical excipients on intestinal absorption of metformin via organic cation-selective transporters","volume":"18","author":"Ruan","year":"2021","journal-title":"Mol Pharm"},{"issue":"6","key":"10.1016\/j.pharma.2025.01.012_bib0615","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1111\/bcp.12476","article-title":"Verapamil decreases the glucose-lowering effect of metformin in healthy volunteers","volume":"78","author":"Cho","year":"2014","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.pharma.2025.01.012_bib0620","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1097\/QAI.0000000000000983","article-title":"The effect of dolutegravir on the pharmacokinetics of metformin in healthy subjects","volume":"72","author":"Song","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"6","key":"10.1016\/j.pharma.2025.01.012_bib0625","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1080\/17425255.2021.1915284","article-title":"Update on drug-drug interaction at organic cation transporters: mechanisms, clinical impact, and proposal for advanced in vitro testing","volume":"17","author":"Koepsell","year":"2021","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"3","key":"10.1016\/j.pharma.2025.01.012_bib0630","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1124\/jpet.114.220350","article-title":"Four cation-selective transporters contribute to apical uptake and accumulation of metformin in Caco-2 cell monolayers","volume":"352","author":"Han","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"10.1016\/j.pharma.2025.01.012_bib0635","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/bdd.755","article-title":"Mechanisms for membrane transport of metformin in human intestinal epithelial Caco-2 cells","volume":"32","author":"Horie","year":"2011","journal-title":"Biopharm Drug Dispos"},{"issue":"3","key":"10.1016\/j.pharma.2025.01.012_bib0640","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1124\/dmd.109.030775","article-title":"Monocarboxylate transporter-mediated transport of gamma-hydroxybutyric acid in human intestinal Caco-2 cells","volume":"38","author":"Lam","year":"2010","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"10.1016\/j.pharma.2025.01.012_bib0645","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ejps.2008.08.004","article-title":"Comparison of drug transporter gene expression and functionality in Caco-2 cells from 10 different laboratories","volume":"35","author":"Hayeshi","year":"2008","journal-title":"Eur J Pharm Sci"},{"issue":"7","key":"10.1016\/j.pharma.2025.01.012_bib0650","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s11095-020-02824-w","article-title":"Metformin transport in native MDCK-Wt and MDCK-II Monolayers unveils functional inter-strains differences influencing drug permeability","volume":"37","author":"Garc\u00eda","year":"2020","journal-title":"Pharm Res"},{"issue":"1\u20132","key":"10.1016\/j.pharma.2025.01.012_bib0655","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ijpharm.2007.12.024","article-title":"Application and limitation of inhibitors in drug-transporter interactions studies","volume":"356","author":"Wang","year":"2008","journal-title":"Int J Pharm"},{"issue":"2","key":"10.1016\/j.pharma.2025.01.012_bib0660","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/jps.21010","article-title":"Variability in Caco-2 and MDCK cell-based intestinal permeability assays","volume":"97","author":"Volpe","year":"2008","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.pharma.2025.01.012_bib0665","series-title":"Pharmaceutical compositions containing propyl gallate as an antioxidant United States patent US5962522A","author":"Wacher","year":"1999"},{"issue":"11","key":"10.1016\/j.pharma.2025.01.012_bib0670","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1016\/j.bcp.2011.08.023","article-title":"Metformin suppresses pregnane X receptor (PXR)-regulated transactivation of CYP3A4 gene","volume":"82","author":"Krausova","year":"2011","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"10.1016\/j.pharma.2025.01.012_bib0675","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1002\/jps.24643","article-title":"Effect of common excipients on the oral drug absorption of biopharmaceutics classification system class 3 drugs cimetidine and acyclovir","volume":"105","author":"Vaithianathan","year":"2016","journal-title":"J Pharm Sci"},{"issue":"1","key":"10.1016\/j.pharma.2025.01.012_bib0680","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s11095-015-1773-4","article-title":"The effect of excipients on the permeability of BCS Class III compounds and implications for biowaivers","volume":"33","author":"Parr","year":"2016","journal-title":"Pharm Res"},{"issue":"3","key":"10.1016\/j.pharma.2025.01.012_bib0685","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0939-6411(00)00081-3","volume":"49","author":"Grattan","year":"2000","journal-title":"Eur J Pharm Biopharm"},{"issue":"10","key":"10.1016\/j.pharma.2025.01.012_bib0690","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1023\/A:1026155822121","article-title":"Comparison of the rates of disintegration, gastric emptying, and drug absorption following administration of a new and a conventional paracetamol formulation, using gamma scintigraphy","volume":"20","author":"Kelly","year":"2003","journal-title":"Pharm Res"}],"container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450925000124?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450925000124?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T12:59:23Z","timestamp":1749905963000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003450925000124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":70,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S0003450925000124"],"URL":"https:\/\/doi.org\/10.1016\/j.pharma.2025.01.012","relation":{},"ISSN":["0003-4509"],"issn-type":[{"value":"0003-4509","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of antioxidant excipients on N-nitrosamine formation and bioequivalence in metformin formulations (review article)","name":"articletitle","label":"Article Title"},{"value":"Annales Pharmaceutiques Fran\u00e7aises","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharma.2025.01.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Acad\u00e9mie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}